Mainz Biomed B.V.

NasdaqCM:MYNZ

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

Germany

Market Cap

USD 5.30 M

Share Price

USD 1.39

Avg Daily Volume

185,512

Change (1 day)

-2.80%

Change (1 year)

-92.26%

Change (YTD)

-67.82%

Mainz Biomed B.V. Free Cash Flow for the year ending December 31, 2024: USD -17.34 M

Mainz Biomed B.V. Free Cash Flow is USD -17.34 M for the year ending December 31, 2024, a -27.24% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Mainz Biomed B.V. Free Cash Flow for the year ending December 31, 2023 was USD -23.84 M, a 54.51% change year over year.
Mainz Biomed B.V. Free Cash Flow for the year ending December 31, 2022 was USD -15.43 M.
Mainz Biomed B.V. Free Cash Flow for the year ending December 31, 2020 was USD -478.42 K, a 14.87% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Free Cash Flow	Operating Cash Flow	Capital Expenditure	Net Cash Used For Investing Activities

NasdaqCM: MYNZ

Mainz Biomed B.V.

CEO	Mr. Guido Baechler
IPO Date	Nov. 5, 2021
Location	Germany
Headquarters	Robert Koch Strasse 50
Employees	19
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.